Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA

Akari Therapeutics, a late-stage biotechnology company, has provided updates on the development of its drug nomacopan for the treatment of pediatric and adult hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The company is making progress towards initiating a Phase 3 study of nomacopan in pediatric HSCT-TMA by the end of 2023. Furthermore, Akari plans to commence..